Mass screening for atrial fibrillation using ECG together with heart failure biomarker does not prevent ischemic stroke or systemic embolism (blood clot) in older adults aged 75–76 years over 5 years follow-up, according to late breaking research presented in a Hot Line Session at this year’s ESC Congress 2024 in London, UK (30 Aug–2 Sept). However, the biomarker may improve the prediction of which individuals have a low risk for ischemic stroke and systemic embolism beyond single-lead ECG in older adults undergoing mass screening for AF.
This article was originally published on MedicalXpress.com